Therapeutic In Vivo Gene Editing Achieved by a Hypercompact CRISPR‐Cas12f1 System Delivered with All‐in‐One Adeno‐Associated Virus
Advanced Science · 2024
DOI: 10.1002/advs.202308095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Tongtong Cui und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Ac…. Hauptthemen laut MEDLINE: Dependovirus, Gene Editing, CRISPR-Cas Systems, Genetic Therapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program, National Natural Science Foundation of China, International Partnership Program of Chinese Academy of Sciences.
Abstract (Originalsprache)
CRISPR‐based gene therapies are making remarkable strides toward the clinic. But the large size of most widely used Cas endonucleases including Cas9 and Cas12a restricts their efficient delivery by the adeno‐associated virus (AAV) for in vivo gene editing. Being exceptionally small, the recently engineered type V‐F CRISPR‐Cas12f1 systems can overcome the cargo packaging bottleneck and present as strong candidates for therapeutic applications. In this study, the pairwise editing efficiencies of different engineered Cas12f1/sgRNA scaffold combinations are systemically screened and optimized, and the CasMINI_v3.1/ge4.1 system is identified as being able to significantly boost the gene editing activity. Moreover, packaged into single AAV vectors and delivered via subretinal injection, CasMINI_v3.1/ge4.1 achieves remarkably high in vivo editing efficiencies, over 70% in transduced retinal cells. Further, the efficacy of this Cas12f1 system‐based gene therapy to treat retinitis pigmentosa in Rho P23H mice is demonstrated by the therapeutic benefits achieved including rescued visual function and structural preservation. And minimal bystander editing activity is detected. This work advances and expands the therapeutic potential of the miniature Cas12f1 system to support efficient and accurate in vivo gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China.
- Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, 100101, China.
- University of Chinese Academy of Sciences, Beijing, 101408, China.
- Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, 100101, China.
Förderung
- National Key Research and Development Program
- National Natural Science Foundation of China
- International Partnership Program of Chinese Academy of Sciences
- China Postdoctoral Science Foundation
- National Key Research and Development Program of China
Zitieren
APA
Cui, T., Cai, B., Tian, Y., Liu, X., Liang, C., Gao, Q., Li, B., Ding, Y., Li, R., Zhou, Q., Li, W., & Teng, F. (2024). Therapeutic In Vivo Gene Editing Achieved by a Hypercompact CRISPR‐Cas12f1 System Delivered with All‐in‐One Adeno‐Associated Virus. Advanced Science. https://doi.org/10.1002/advs.202308095
Vancouver
Cui T, Cai B, Tian Y, Liu X, Liang C, Gao Q, et al. Therapeutic In Vivo Gene Editing Achieved by a Hypercompact CRISPR‐Cas12f1 System Delivered with All‐in‐One Adeno‐Associated Virus. Advanced Science. 2024. doi:10.1002/advs.202308095
BibTeX
@article{Cui2024,
author = {Cui, Tongtong and Cai, Bingyu and Tian, Yao and Liu, Xin and Liang, Chen and Gao, Qingqin and Li, Bojin and Ding, Yali and Li, Rongqi and Zhou, Qi and Li, Wei and Teng, Fei},
title = {Therapeutic In Vivo Gene Editing Achieved by a Hypercompact CRISPR‐Cas12f1 System Delivered with All‐in‐One Adeno‐Associated Virus},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202308095}
}
EUVIMED